Partners Sanofi-Aventis and Regeneron Pharmaceuticals report positive results for a late stage study evaluating Zaltrap (aflibercept), a colorectal cancer candidate.  

The two companies announced that the phase III VELOUR trial evaluating Zaltrap, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer (mCRC).

George Yancopoulos, chief scientific officer at Regeneron, said "these findings are exciting given the limited second-line treatment options for patients with mCRC.”